{"schema_version":"secwatch.filing_event.v1","accession":"0000037785-23-000181","form_type":"8-K","ticker":"FMC","cik":"0000037785","company_name":"FMC CORP","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.674672+00:00","generated_at":"2026-06-08T01:36:53.723679+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FMC outlines strategic growth plan; sees 2024 revenue $4.65-4.85B, adj. EBITDA $1.025-1.125B","bullets":["2024 revenue guidance $4.65-4.85B (midpoint +3% vs latest 2023); adj. EBITDA $1.025-1.125B (midpoint +8%).","Restructuring to deliver $50-75M adj. EBITDA contribution in 2024; ~$150M run-rate savings by end-2025.","2026 goals: revenue $5.5-6.0B, adj. EBITDA $1.3-1.5B, adj. EPS growth > EBITDA, ROIC mid-teens %.","Targeting ~2x net debt/adj. EBITDA by end-2024; free cash flow conversion >100% in 2024.","CEO Mark Douglas cites R&D pipeline and biologicals portfolio as growth drivers."],"urls":{"canonical":"https://secwatch.observer/filing/0000037785-23-000181","json":"https://secwatch.observer/filing/0000037785-23-000181.json","markdown":"https://secwatch.observer/filing/0000037785-23-000181.md","text":"https://secwatch.observer/filing/0000037785-23-000181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/37785/000003778523000181/0000037785-23-000181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/37785/000003778523000181/fmc-20231116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:36:53.723679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}